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Abstract
The cause(s) of sporadic Alzheimer’s disease (sAD) are complex and currently poorly understood. They likely result from a combination
of genetic, environmental, proteomic and lipidomic factors that crucially occur only in the aged brain. Age-related changes in calcium
levels and dynamics have the potential to increase the production and accumulation of both amyloid- peptide (A) and  pathologies
in the AD brain, although these two pathologies themselves can induce calcium dyshomeostasis, particularly at synaptic membranes.
This review discuses the evidence for a role for calcium dyshomeostasis in the initiation of pathology, as well as the evidence for these
pathologies themselves disrupting normal calcium homeostasis, which lead to synaptic and neuronal dysfunction, synaptotoxicity and
neuronal loss, underlying the dementia associated with the disease.
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Introduction
Alzheimer’s disease (AD) is an age-related neurodegenerative dis-
order, which is characterized by progressive memory loss and
behavioural changes that become more apparent and more severe
as the disease progresses, and accounts for up to 70% of all
dementias. Underlying these phenotypic changes are the appear-
ance of several hallmark pathologies. The first is the accumulation
of the amyloid- peptide (A) into extracellular plaques, whereas
the second is the formation of neurofibrillary tangles (NFTs) com-
posed of hyperphosphorylated  protein within neurons [1]. The
consequence of the development of these two pathologies is wide-
spread synaptic and neuronal loss, such that a brain with advanced
AD can weigh 33% less than a brain from an aged-matched con-
trol. AD research has focused on two main areas – the first is in
understanding what causes the accumulation of these two patholo-
gies in the aged brain, and the second is understanding how the
presence of these pathologies affects the local brain environment
to cause the widespread synaptic and neuronal loss, and cognitive
decline. Through understanding, it is possible that (1) the accumu-
lation of pathologies in the aged brain can be delayed, prevented,
or even reversed, and that (2) the neurodegenerative properties of
the pathologies can be dampened. Over the past 20 years aberrant
calcium dysregulation has been consistently implicated in AD [2, 3],
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either in the initiation of the disease, the progression of AD-related
pathologies, or in mediating the neuronal and synaptic loss that
results from the presence of the pathologies.
Calcium is an integral signalling molecule whose local and
global levels are tightly regulated at a temporal and spatial level
as elevations in calcium activate a number of cellular signalling
pathways including those crucial for learning and memory such
as CamKII and CREB, as well as cell death pathways. In most cell
types’, cytosolic calcium levels are kept low (~100 nM) relative to
the extracellular space and the intracellular stores by calcium-
binding buffering proteins (e.g. calbindin), and via the extrusion
of cytosolic calcium across the plasma membrane through cal-
cium ATPase pumps and exchangers, and also due to sequestra-
tion into intracellular stores such as the endoplasmic reticulum
(ER) and mitochondria. Calcium influx into the cytosol occurs
across the plasma membrane via store-operated calcium chan-
nels, voltage-gated calcium channels or from internal stores. The
ER is the largest intracellular store, maintaining a high calcium
concentration (100–500 M) via the unidirectional pumping of
cytosolic calcium into the ER lumen by SERCA. Calcium release
from the ER into the cytosol occurs via two types of calcium
channels: IP3Rs and RyRs. IP3R-mediated release is regulated at
the plasma membrane by ligand binding to specific G-protein
coupled receptors that induce phospholipase C to cleave phos-
phatidylinositol-4, 5-bisphosphate into diacylglycerol and IP3,
which then binds to the IP3R in the ER membrane. Calcium influx
across the plasma membrane occurs due to depolarization,
through VGCCs, and glutamate receptors such as the NMDA
receptor and the mGluR.
Familial and sporadic AD
The overwhelming majority of AD cases occurs with no obvious
environmental or genetic cause and is known as sporadic AD
(sAD). It typically manifests at a late age of onset of more than
65 years. Around 5% of all AD cases, however, have a
Mendelian pattern of inheritance and these are referred to as
familial AD (fAD). The age of onset of dementia in fAD can vary
dramatically, but typically fAD cases occur at much younger
ages (from 30 years or more), and their dementia is usually
more severe and progresses more rapidly. Clinically, and neu-
ropathologically, both sAD and fAD are very similar, with all
patients exhibiting widespread plaque and tangle pathologies
with extensive neuronal loss.
APP processing and the amyloid cascade hypothesis
Studies have shown that cases of fAD are accounted for by muta-
tions in only three genes – the amyloid precursor protein (APP)
gene [4, 5], presenilin 1 (PS1) gene [6] and presenilin 2 (PS2)
gene [7]. APP is a large membrane spanning protein that contains
the A peptide sequence [4]. A is sequentially cleaved from APP.
An enzyme identified as BACE first cleaves APP [8] to produce a
99 amino acid stub within the membrane known as C99. C99 is
then cleaved by a complex known as -secretase to release A [9,
10]. Presenilins comprise the catalytically active subunit of the -
secretase complex (which also includes nicastrin, APH-1 and
PEN-2 [11]), and thus are essential for release of the A peptide.
Although the BACE cleavage site of APP occurs at a specific
sequence, the -secretase cleavage has loose sequence specificity
and can cleave C99 between 38 and 43 amino acids from the 
N-terminal, to release A peptides of variable lengths. The most
common lengths are 1–40 and 1–42. A1–40 is 10–20 times more
abundant than A1–42. Mutations in presenilins associated with
fAD increase the production of A1–42 at the expense of shorter
A peptides [12], whereas mutations in APP are associated with
increased BACE cleavage [13], A structural misfolding [14], or
an increased prevalence of A1–42 at the expense of shorter A
peptides [15].
APP cleavage by BACE and -secretase to generate A is not the
predominant APP processing pathway. More commonly APP is
cleaved by an enzyme with -secretase activity, at a site juxtaposed
to the membrane, to release the large ectodomain known as sAPP,
as well as an 83 amino acid stub within the membrane known as
C83. -secretase cleavage occurs within the A sequence to pre-
clude A production. Hence, stimulation of -secretase cleavage
leads to reduced A production [16], and is a possible therapeutic
target for the disease.
The production of A alone is not sufficient to be toxic, and
many studies have highlighted the aggregation state of A as
being crucial to its toxicity in vitro [17, 18], its ability to impair
learning and memory [19] as well as long-term potentiation (LTP)
[20, 21], in vivo [22]. A1–42 aggregates more readily than A1–40,
and forms the majority of A species present within AD plaques,
explaining why mutations that affect the A 40/42 ratio cause fAD
without affecting total A levels. More recently, soluble oligomers
have been identified as the disease active state of A, and include
dimers and trimers [23, 24] to dodecamers [19] and beyond.
The sum of these findings led to the amyloid cascade hypoth-
esis, which states that the accumulation of A causes both sAD
and fAD, and the downstream consequences of A accumulation
lead to  pathology and ultimately synaptic and neuronal loss [25].
Although the causes of fAD are for the most part understood,
the cause(s) of sAD are poorly understood. It should be noted
that both sAD and fAD are age-related – despite fAD mutations
in APP and PS1/2 being present from birth, dementia onset usu-
ally requires many decades to manifest suggesting that either
pathology accumulation is very slow, or that the younger brain is
better able to cope with the increased A pathology that these
mutations lead to, either via its degradation or by protecting
against the downstream effects of A accumulation. With sAD,
the cause of pathology development and consequent dementia is
not well understood. It likely results from combinations of
genetic, environmental, proteaomic and lipidomic interactions
resulting in the accumulation of AD-related pathologies.
Understanding both the causes for the appearance of AD-related
pathologies and the effects of these pathologies on the local
brain environment is crucial in order to understand, prevent or
treat the disease.
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Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
J. Cell. Mol. Med. Vol 13, No 9A, 2009
2789
This review will discuss the possibilities that calcium plays in
both disease initiation, progression, and as a disease effector
molecule, as summarized in Fig. 1. Notably, the presenilins, in
addition to being the catalytic subunit of the -secretase com-
plex, are also key regulators of ER calcium homeostasis and
have been reported to regulate SERCA [26], IP3 receptors [27]
and ryanodine receptors [28] and also reported to form calcium
conducting ER leak channels themselves [29]. fAD linked PS
mutations have profound effects on calcium signalling [30], but
the significance of this to fAD disease progression is unclear as
mutations that affect A accumulation/increased production are
sufficient to cause fAD without these additional effects on cal-
cium caused by PS mutations. Thus it seems that, at least with
respect to fAD, fAD linked PS mutations alter A metabolism to
give rise to fAD, and additionally affect calcium homeostasis
which may or may not affect disease progression. The effects
and implications of presenilin regulation of both calcium and -
secretase activity will not be discussed in this review as it was
recently covered elsewhere [31].
Calcium in the initiation of pathology
Effects of calcium on APP processing 
and A deposition/aggregation
APP processing lies at the heart of AD, and a majority of therapeu-
tics are designed to alter APP processing to prevent the production
of A, to prevent the disease and to halt further progression [32].
Ultimately A accumulation is the tenet of the disease, and accu-
mulation occurs due to an increase in production during aging, a
decrease in degradation or a change in predisposition to aggregate.
For example, changes in APP metabolism can produce more aggre-
gate prone A1–42 at the expense of shorter A peptides.
Genetic linkage in calcium related genes and AD
Calcium has been implicated both in the development of sAD
through genetic susceptibility, as well as altered A production
© 2009 The Author
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Fig. 1 Involvement of calcium in AD progression: A number of factors can increase the likelihood of an individual developing sporadic AD. These could
include changes in age-related calcium handling which result in increased calcium fluxes. Such increases are associated with increased production of
A, and also with reductions in macroautophagy – a clearance pathway for intracellular aggregates. Many genetic polymorphisms have been identified
which can increase the risk of developing AD, including several calcium related genes. Notably, environmental and lifestyle appear to offer both great
protection and also risk to developing AD. Accumulation of A is considered one of the primary steps in developing AD. A can aggregate into oligomers
and fibrils, which can themselves alter cellular calcium homeostasis leading to increased calcium influx into neurons, astrocytes, but also into specific
compartments such as mitochondria and synapses. Elevation of calcium can lead to synaptic dysfunction, and subsequent cognitive deficits. Over time
these synaptic dysfunctions could lead to synaptic loss, and eventually the neuronal loss that plagues the late stage AD brain. A aggregates can also
lead to  phosphorylation, via reductions in the ubiquitin-proteasome system, increases in  kinases and decreases in  phosphatases. Increases in cal-
cium influx have been associated with activation of  kinases and may also contribute to the development of NFTs.
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and metabolism. A number of genes are associated with increased
risk of developing sAD, most notably the apo4 allele [33].
Recently, a polymorphism in a gene encoding a novel calcium
conducting channel was found to have linkage to sAD [34],
although this same polymorphism was shown not to have linkage
in three separate studies of Caucasian populations [35–37]. This
channel is called calcium homeostasis modulator 1 (CALHM1)
and is a conserved three-transmembrane domain containing gly-
coprotein. It localizes to both the ER and the plasma membrane.
Overexpression of this channel induces a cytosolic calcium influx
pathway, which is unaffected by conventional calcium channel
blockers, but prevented by the removal of extracellular calcium
and non-specific ion channel pore blockers. The induction of this
particular calcium influx route into the cytosol results in an
increase in sAPP production, with a concomitant reduction in
A, suggesting an effect on one of the -secretase enzymes.
Notably, knockdown of this channel, or the presence of the identi-
fied polymorphism for sAD (rs2986017 encoding P86L substitu-
tion) decreases calcium permeability and increases A produc-
tion. These data provide strong evidence that calcium signalling
and influx can contribute to the initiation of AD pathology in the
aged brain, and that specific calcium pathways can affect APP
metabolism. Although further studies are required to replicate the
linkage of the CALHM1 rs2986017 polymorphism to sAD, this
important finding shows how changes in calcium influx pathways
can alter APP processing and A production.
Since a polymorphism in the CALHM1 gene has linkage to
increased risk of sAD, it begs the question whether other known
risk factors could also directly involve altered calcium homeosta-
sis. One study has shown an association between the NMDA recep-
tor NR2B subunit gene promoter polymorphism and development
of sAD in a North China population [38]. The NMDA receptor is an
important focal point in AD, both in modulating the appearance of
A and  pathology, and also in mediating A-induced synaptic
and behavioural deficits in the disease process. Offering a direct
correlation between calcium and cognitive decline, serum calcium
levels correlate well with cognitive decline during aging, with ele-
vated serum calcium levels being associated with worse cognitive
function [39], and also a faster rate of decline. A regulator of serum
calcium levels, the calcium-sensing receptor – is associated with
development of AD, particularly with a dinucleotide repeat poly-
morphism within the promoter sequence [40].
Apo4 and calcium
Of note, the presence of the Apo4 allele is a strong risk factor for
the development of sAD [33] – with ~50% of sAD patients having
at least one copy of the Apo4 allele. Despite the significant impact
of this lipid transporter on AD, we do not fully understand its role
in disease progression. The Apo genotype modulates elevated
serum calcium and cognitive decline [41]. High serum calcium is
associated with worse cognitive function especially in Apo4 carri-
ers, but this interaction is lost in Apo2 carriers [41]. Furthermore,
the Apo4 allele is associated with increased calcium rises in neu-
ronal cultures, which can mediate cell death [42], and also in
SHSY5Y cultures where increased calcium influxes increase
GSK3 activity leading to reduced cell viability [43]. Apo4 appears
to affect calcium influx into neurons via plasma membrane calcium
channels [42], which, as discussed below, can alter APP process-
ing leading to increased production of A.
Calcium and APP processing
In addition to CALHM1, a number of other studies have reported
altered calcium homeostasis affecting the -secretase dependent
processing of APP. Increasing calcium influx into the cytosol with
the ionophore ionomycin leads to increased sAPP production
[44], whereas calcium influx through the NMDA receptor
increases sAPP production and decreases A generation [45].
However, despite calcium influx through certain channels stimu-
lating -secretase processing of APP, the vast majority of studies
have shown that increased calcium influx, and elevated cytosolic
calcium levels, leads to a net increase in A production [46–48].
More recently, data have highlighted the ER calcium stores as
playing an important role in the regulation of A production. We
have shown that inhibition of SERCA, either with thapsigargin or by
siRNA knockdown, leads to a robust reduction in A generation
whereas overexpression of SERCA increases A generation [26]. In
agreement with ER calcium stores playing a regulatory role in A
generation, knockdown of the IP3 receptor also reduces A gener-
ation [27]. In concert, calcium release from the ER via the ryanodine
receptor increases A production [49], whereas capacitative cal-
cium entry (CCE), a calcium influx pathway across the plasma
membrane, affects APP metabolism with inhibition of CCE leading
to increased A 1–42 production [50]. Taken together these studies
point to ER calcium as a key regulator of A generation, as well as
calcium influx across the plasma membrane through channels such
as CALHM1 and CCE channels, and demonstrates how age- or envi-
ronment-dependent changes in neuronal calcium homeostasis
could alter APP processing to drive the increased production of A,
or altered metabolism to preferentially generate A1–42.
Synaptic regulation of A production
Adding a new dimension to these in vitro experiments, in vivo
studies have allowed a new insight into how the workings of neu-
ronal networks can regulate A production, in both mouse models
of AD and also in the human brain [51]. Synaptic activity is
dependent upon calcium, both at the pre- and post-synaptic termi-
nals, for exocytosis of neurotransmitters across the synaptic cleft,
as well as initiation of action potentials at the post-synaptic mem-
brane. In slice cultures from APP overexpressing mice, increased
synaptic activity led to increased production of A, whereas inhibi-
tion of synaptic activity suppressed A generation [52]. Synaptic
activity affects APP processing at either the - or -secretase 
levels, as levels of C99 were modulated. Using microdialysis, and
subsequent analysis of interstitial A, it was shown that synaptic
activity also regulated A production in vivo [53]. Decreased
synaptic activity, elicited by tetrodotoxin (TTX) administration,
reduced A and partially corresponded to increased C83 levels,
© 2009 The Author
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suggesting an increase in -secretase or a decrease in BACE 
processing of APP with decreased synaptic activity. TTX inhibits
action potentials by blocking Na channels, to prevent 
calcium influx at the pre-synaptic terminal and subsequent exocy-
tosis of neurotransmitters and concomitant endocytosis of synaptic
vesicles. Hence, TTX application is likely associated with a decrease
in synaptic calcium and a decrease in A generation/secretion.
Furthermore, A production and secretion are dependent upon
synaptic vesicle membrane recycling; increasing synaptic activity
leads to synaptic APP being recycled into endosomes where A
generation occurs which is then secreted from the neuron [54].
Though synaptic activity modulates both endocytosis of APP into
A-generating endosomes and also exocytosis of neurotransmitter
containing vesicles, it is unclear if A is secreted from synapses
alongside neurotransmission or in a more passive manner.
Furthermore, synaptic activity increases A oligomer formation in
a synaptic cleft zinc dependent manner [55], suggesting that
synaptic activity can not only increase A generation/secretion but
it can also drive it to aggregate into toxic oligomeric species. Of
interest, it seems that secreted A at synapses is able to regulate
synaptic function through depression of excitatory transmission by
an NMDA receptor-mediated pathway [52], suggesting that A is
purposely secreted from the pre-synaptic terminal in order to play
a role in synaptic plasticity. How this role differs between healthy
controls and AD patients is unknown, but may suggest a calcium
dependent physiological role for A at the synapse.
Normal age-related changes in calcium 
homeostasis and AD pathology
Normal brain aging involves subtle changes in cognition and brain
functioning, attributed in part to age-related changes in how neu-
rons shuttle calcium from their various internal stores, and altered
calcium influx across the plasma membrane. These changes are
likely due, partially, to an increased presence of reactive oxygen
species, as well as transcriptional and post-translational changes in
the calcium channels and receptors themselves. Age-related
changes in neuronal calcium handling have been elegantly reviewed
elsewhere [3, 56, 57], but the consensus is that aged neurons tend
to have increased resting cytosolic calcium levels [58–60] as well as
increased cytosolic calcium fluxes due to increased calcium entry
through voltage gated calcium channels [61, 62]. This increased
influx, in turn, stimulates calcium release from the ER via the ryan-
odine receptor [63, 64] resulting in further elevated cytosolic cal-
cium fluxes. Voltage gated calcium channels, such as the L-type, are
known to be modulated by reactive oxygen species [65], as well as
by A [66], both of which are increased through the aging process.
Furthermore, aged neurons appear to have reduced calcium buffer-
ing capabilities due to reductions in the levels of cytosolic calcium
binding proteins such as calbindin D28K [67] and calreticulin [68],
reduced mitochondrial buffering capabilities [69], and a decrease in
SERCA function [70], at least in peripheral nerves, resulting in pro-
longed calcium fluxes. Interestingly, IP3 evoked calcium fluxes
appear to decrease in aged neurons [71], perhaps due to a dimin-
ished chemical gradient due to elevated cytosolic calcium. Hence,
age related increases in cytosolic calcium levels could conceivably
alter APP processing as discussed above, and shift APP metabolism
to produce increased amounts of A.
Along these lines, aging is associated with a decrease in cal-
cium currents through NMDA receptors in neurons [56]. Since
current through the NMDA receptor is associated with increased
-secretase processing of APP [45], it suggests that age-related
reductions in NMDA receptor calcium would no longer stimulate
the -secretase enzymes to the same degree, resulting in a shift
to A generation. Due to the presence of age-related changes in
calcium, coupled with the observations that calcium regulates
synaptic plasticity and increases in calcium leads to neuronal cell
death, the calcium homeostasis disruption theory of AD was first
postulated over 20 years ago [2], and remains a viable theory for
the appearance of AD in the aging brain.
Age-related reductions in autophagy
Alterations in neuronal calcium may also affect AD-related pathol-
ogy through indirect means. Of interest, AD and many other neu-
rodegenerative diseases are age dependent even when mutations
in key genes force the aggregation of proteins into toxic conforma-
tions. What is the protection that the youthful brain provides
against these proteinaceous aggregates seen in neurodegenerative
diseases that the aged brain does not afford? Protein turnover is
crucial both in neurodegenerative diseases as well as normal and
successful aging. Cytosolic proteins are degraded by either the
ubiquitin proteasome system, or by the lysosome system through
macroautophagy or chaperone mediated autophagy. The UPS sys-
tem is impaired in AD patients [72], and proteasome inhibition
increases levels of both  and A in vivo [73]. Notably, autophagy
is crucial for the removal of cytosolic aggregates especially those
implicated in neurodegenerative diseases [74]. Age-related 
reductions in autophagy are implicated in allowing the aged 
brain to develop neurodegenerative diseases, whereas stimulators 
of macroautophagy have proven successful in mouse models of
Huntington’s disease, by removing cytosolic aggregates of expanded
huntingtin protein from neurons [75]. Cytosolic calcium levels are
potent regulators of macroautophagy. Inhibition or depletion of the
IP3 receptor, and L-type voltage gated calcium channel blockers
[76] are associated with increased autophagy. Age-related
increases in L-type calcium currents and overall increases in
cytosolic calcium levels may negatively influence macroautophagy,
allowing the buildup of cytosolic proteins in aged neurons such as
hyperphosphorylated , -synuclein and huntingtin.
Calcium in disease progression
Linking A and 
Although no mutations or polymorphisms in the  gene (MAPT)
are associated with sAD or fAD,  protein is the component of the
© 2009 The Author
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second hallmark pathology of AD – the NFTs [77]. NFTs are com-
posed of aggregated hyperphosphorylated  and are found in the
soma and dendrites of neurons.  is a microtubule-associated pro-
tein that acts to stabilize microtubules enabling efficient axonal
transport.  can be phosphorylated on a number of threonine and
serine residues by an expanding list of kinases, most notably
cyclin dependent kinase 5 (Cdk5) [78] and glycogen synthase
kinase 3 [79]. Abnormal hyperphosphorylation occurs in AD and
leads to the disruption of axonal transport and the subsequent
relocalization and aggregation of the modified  proteins into
structures known as paired helical filaments, which comprise the
NFTs. Of note, NFT formation is sufficient to cause extensive neu-
rodegeneration on its own. Mutations in the  gene are associated
with a group of dementias known as tauopathies, including fron-
totemporal dementia with parkinsonism linked to chromosome 17
[80]. Due to the genetic data that gives rise to fAD,  hyperphos-
phorylation is generally considered to be a downstream event of
A accumulation, but is thought to be a crucial effector molecule
that causes synaptic and neuronal loss [81, 82]. This hypothesis
is supported by data showing that A accumulating transgenic
mice develop cognitive impairments, but when the  gene is
knocked out the A pathology remains stable but the mice no
longer develop cognitive impairments [83]. We have also demon-
strated recently that treatment of 3	Tg-AD mice with the sirtuin
inhibitor nicotinamide prevents cognitive deficits by removing 
phosphorylated at threonine 231, with no effects on A [84]. Any
factor that impacts  phosphorylation has the potential to play an
important role in disease progression in AD. Given that many
kinase and phosphatase pathways are activated by calcium, there
has been a great deal of interest in studying the pathways that lead
to  hyperphosphorylation through both A dependent and inde-
pendent pathways. In the AD brain, post-mortem studies have
highlighted changes in calcium channels and pumps that correlate
with severity of  pathology, including a reduction in ryanodine
receptor binding [85] and IP3 receptor binding [86], in cases 
with high pathology, suggesting that either NFT formation down-
regulates these calcium pumps which may contribute to neurode-
generation, or that a down-regulation of these pumps (perhaps by
A pathologies) encourages NFT formation.
Calcium, calpains and  pathology
A induced increases in calcium lead to  hyperphosphorylation
via both GSK3 and Cdk5 [87]. Cdk5 activity is regulated through
its interactions with cyclin-related activator molecules such as
p25, p35, p29 and p39. A increases the activity of Cdk5 by pro-
moting the Cdk5-p25 and p35 complexes [88–90]. p39/p35 is
cleaved to p29/25 by calpains [91], releasing it from a membrane
tether where it forms unregulated functional complexes with Cdk5
leading to  hyperphosphorylation [92]. Activation of calpain is
calcium dependent, and aberrant activation of calpains 1 and 2 has
been linked to AD [93, 94]. Calpain 2 has increased activation in
NFT bearing neurons and neurites [95], whereas a calpain sub-
strate, calcineurin, is truncated in the AD brain [96]. Hence, A-
mediated and age related increases in cytosolic calcium can lead
to the activation of calpains, which then lead to hyperphosphory-
lation of  via Cdk5 [97]. Of note, a recent study highlighted how
calpain activation in transgenic mouse models of AD leads to
synaptic dysfunction and behavioural impairments [98]. Calpain 1
is expressed in dendritic spines [99], which have abnormally ele-
vated basal calcium levels in close proximity to A plaques [100]
which would have the potential to activate these synaptic calpains.
The application of a calpain inhibitor restores synaptic deficits and
spatial memory to wild-type levels, demonstrating the role acti-
vated calpain plays in mediating A-induced synaptic dysfunction
and cognitive decline [98]. Calpain inhibitors also prevent A-
mediated cleavage of  protein into toxic fragments, in particular a
17 kD fragment [101], suggesting that A-induced calcium influx
leads to calpain dependent neurotoxicity via cleavage of  protein,
and others including dynamin 1 [101, 102]. These effects could be
prevented by blocking calcium influx through the NMDA receptor
[102] implicating A, NMDA receptor mediated calcium influx,
calpains,  and neurotoxicity. Along these lines, overexpression of
 itself can lead to increased NMDA receptor activation, leading to
increased calcium influx and subsequent activation of calpain,
cleavage of  to produce the aforementioned toxic 17 kD fragment,
and subsequent neuronal loss [103]. This suggests that A-
induced increases in synaptic calcium could lead to  pathologies
via calpain activation, but that  pathologies themselves could
then influence further increases in synaptic calcium levels through
the NMDA receptor.
Calcium as a disease effector
The discovery of a polymorphism in the CALHM1 gene, linking
calcium influx to A generation and an increased risk of develop-
ing AD provided concrete evidence for a role for calcium in the
initiation of sAD [34], but so far three further linkage studies have
failed to replicate the association to sAD [35–37]. Despite this,
the evidence that age-related changes in neuronal calcium home-
ostasis could affect APP processing and A metabolism is com-
pelling and offers potential therapeutic targets to try and reverse
these changes in calcium, and hence APP processing. However,
the appearance of A in old age is only the first step in neurode-
generation and dementia, and there is overwhelming evidence
that (1) A induces disturbances in neuronal and synaptic cal-
cium homeostasis and (2) that such changes in neuronal and
synaptic calcium would lead to synaptic and neuronal toxicity as
sustained increases in cytosolic calcium render neurons suscep-
tible to additional metabolic insults, as well as being able to
induce cell death pathways itself. Additionally, given the evidence
that altered neuronal calcium fluxes and synaptic activity can alter
A generation and secretion, A-induced calcium fluxes could
further augment A generation in a positive feedback pathway,
accelerating disease progression.
The effects of A on calcium can be categorized into several
overlapping groups. The first is a large body of literature
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demonstrating how A can influence existing calcium conducting
channels directly, including L-type voltage-gated calcium channels
[65, 66, 104–107], P/Q type voltage-gated calcium channels
[108], glutamate receptors including the NMDA receptor
[109–112], the AMPA receptor [113] and the mGluR [114], and
also nicotinic receptors [115–118]. The second group consists of
numerous reports that A can itself form unregulated calcium
conducting pores within lipid membranes [119, 120]. Thirdly,
there are reports that the presence of A affects calcium buffer-
ing, either by affecting intraneuronal calcium sinks/stores or by
affecting steady state levels of cytosolic calcium buffering proteins,
such as calbindin [121]. Finally, there are also reports that A can
affect synaptic transmission, which influences calcium influx at
both the pre- and post-synaptic membranes, and is essential for
neuronal functioning and cognitive function. The effects on synap-
tic transmission are likely a consequence of A inducing calcium
dyshomeostasis, as well as a cause of further calcium dyshome-
ostasis.
Synaptic calcium dyshomeostasis and AD – a focus 
on NMDA receptors
Synaptic loss is the best correlate to dementia in the AD brain,
although A and  loads associate poorly with dementia. In addi-
tion to this, work with transgenic mouse models, which overex-
press A, has shown that A induces memory and LTP impair-
ments without overt neuronal loss, and can do so in an acute fash-
ion. As such the site of neuronal plasticity, the synapse, is high-
lighted as a crucial target for the A peptide as disturbances here
would interfere with both LTP and learning and memory, but
would only lead to neuronal loss over extended periods of time,
possibly beyond the lifespan of rodents. Neuronal synapses con-
tain dense concentrations of calcium conducting channels, as well
as cytosolic calcium buffering proteins, and a variety of calcium
dependent signalling pathways also implicated in LTP and learning
and memory such as calcineurin, CaMKII and CREB, all of which
have been reported to be changed in AD brains and APP overex-
pressing transgenic mice. Hence, in order to satisfy the observa-
tion that A acutely impairs LTP and learning and memory, but
chronically leads to widespread synaptic and neuronal loss, the
effects of A on calcium could initially be at the synaptic level, but
with the ability to lead to widespread neuronal loss over time.
One of the most significant advances in recent years in AD
research has been the discovery that it is the aggregation state of
A that is crucial to its pathophysioloigcal effects, particularly
when describing calcium dependent events. Soluble A oligomers
appear to mediate calcium dysfunction, as well as inhibit LTP
[122], a form of synaptic plasticity, which relies upon calcium
fluxes and is thought to underlie learning and memory [123]. The
NMDA receptor appears to be a focal point for A oligomer
induced calcium dysfunction and LTP inhibition [124], as well as
NMDA receptor mediated synaptic loss [125], and A oligomers
associate and co-localize with dendritic arbours [126, 127] – post-
synaptic membranes enriched in NMDA receptors. Synaptic activ-
ity can increase generation/secretion of A at synapses, but can
also stimulate the aggregation of monomeric A into oligomeric
species. This aggregation of synaptic A appears to be modulated
by synaptic zinc, a known facilitator of A aggregation, and by the
NMDA receptor, as inhibition of NMDA calcium current influx with
antagonists or with zinc chelators prevents synaptic A oligomer-
ization [55]. Intriguingly, synaptic zinc is a known competitive
antagonist at the NMDA receptor [128], and is released into the
synaptic cleft alongside glutamate, serving to depress synaptic
transmission, yet here zinc promotes A oligomerization suggest-
ing that the inhibitory effect of endogenous synaptic zinc on the
NMDA receptor is not sufficient to overcome A oligomerization.
What is the consequence of A, or A oligomers, associating with
NMDA receptors at synapses? It appears that A may have a
physiological role in regulating synaptic plasticity via the NMDA
receptor, as A secreted from synapses causes NMDA receptor
dependent synaptic depression [52], which could arise due to
increased endocytosis of the NMDA receptor in the presence of A
[109, 111]. This function may go awry in the AD brain where A
oligomer formation is promoted, as A oligomers interact with
NMDA receptors to promote calcium influx into post-synaptic
membranes [129], or this NMDA receptor mediated synaptic
depression may be enhanced as it has been reported that A
oligomers decrease calcium currents through the NMDA receptor
resulting in synaptic loss [125].
In addition to A oligomers interacting with post-synaptic
NMDA receptors, they have also been shown to affect pre-synaptic
calcium conducting channels including the P/Q type voltage gated
calcium channels [108] at very low nanomolar concentrations.
Calcium currents through the P/Q type channels were found to be
suppressed in the presence of aggregated, but not monomeric, A
resulting in decreased synaptic transmission, as exocytosis at the
pre-synaptic membrane is dependent upon calcium influx. The
authors suggested that this reduced synaptic activity could lead to
synaptic loss, as long-term withdrawal of synaptic activity is asso-
ciated with synaptic retraction. This effect would be enhanced by a
concomitant decrease in NMDA receptor calcium influxes in the
post-synaptic membrane, in the presence of A oligomers.
Thus it seems that there are at least two competing theories for
the mode of action of A oligomers at the synapse. It is well
defined that A oligomers inhibit LTP, and this appears to be
through an NMDA receptor dependent mechanism [124]. One the-
ory is that LTP is impaired due to an inhibition of calcium current
at the post-synaptic membrane, due to inhibition of the NMDA
receptor, and perhaps a reduction in pre-synaptic activity. A lack of
synaptic activity would lead to synaptic retraction over time, in
accordance with reduced synapses and synaptic proteins in AD and
APP transgenic mice brains. The other would suggest that A
oligomers induce increased calcium influx at the synapse, leading
to excitotoxicty, and synaptic dysfunction, and eventual synaptic
and neuronal loss. This is in accordance with the evidence that
dendritic spine calcium is elevated in close proximity to A plaques
[100], and the evidence of activated calcium dependent proteases
and calcium dependent signalling pathways at synaptic sites. Both
would impair LTP, and lead to synaptic loss, but the discrepancies
could be due to spatial and temporal reasons – either different 
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populations of synapses are affected differentially, or the acute
effects of A oligomers are different from chronic exposure.
A elevates cytosolic intracellular calcium levels in vivo
Supporting a role that chronic A oligomer exposure leads to
increased calcium influx, live imaging of neurites in APP overex-
pressing mice, revealed elevated dendritic spine basal calcium lev-
els correlating well with close proximity to A plaques [100], indi-
cating once again that the aggregation state of A is crucial but
also that the net result of A interactions with synaptic chan-
nels/proteins, is elevated calcium. Although the source of
increased basal cytosolic calcium is not yet elucidated, it is likely
a key event in synaptic dysfunction, as spines with elevated cal-
cium displayed altered morphology tending towards a beaded or
dysmorphic appearance. These morphological changes could be
rescued by application of calcineurin inhibitors; calcineurin is a
calcium dependent phosphatase important for learning and mem-
ory as well as LTP, indicating that increased resting calcium levels
were atypically activating this phosphatase, whereas calcineurin
inhibitors partially restore learning and memory deficits in APP
transgenic mice [130]. In addition to calcineurin, other spine
located calcium dependent enzymes have been implicated in
synaptic dysfunction due to the presence of A – in particular cal-
pain inhibitors, as discussed, also prevent A induced LTP and
learning and memory deficits caused by the presence of the A
peptide [98].
In addition to neurons, astrocytic networks display elevated
cytosolic calcium levels, and demonstrate an increased frequency
of calcium transients both intracellulalry and intercellularly, in APP
overexpressing mice [131]. The mechanism of action is distinct
from that which causes increased dendritic spine elevations in cal-
cium as astrocytic calcium is unaffected by proximity to A
plaques. This suggests that A aggregation state is less important
to the effects on astrocytes, and is likely an easily diffusible wide-
spread A species, such as a monomer or dimer. Furthermore,
astrocytic calcium dyshomeostasis is not derived, nor related, to
neuronal activity, as blocking action potentials does not ameliorate
elevated calcium levels or transients in astrocytes. These observa-
tions lead to speculation about the implications of widespread
astrocytic calcium dyshomeostasis on AD progression. For exam-
ple, it shows that astrocytes could be severely impacted as a result
of pathology in AD, yet this does not seem to lead to astrocyte loss
but could be indirectly contributing to the synaptic and neuronal
loss seen in the disease, as astrocytes play a large supporting role
for neuronal function and survival. As APP is also expressed in
astrocytes could these A induced changes in calcium lead to
changes in APP processing in astrocytes in human beings – a pos-
itive feedback on A production? Further experiments will be
needed to answer these questions, as well the source of elevated
dendritic spine calcium in close proximity to A plaques.
The relationship between neuronal calcium dyshomeostasis
and proximity to A plaques was confirmed by looking at cortical
neuronal calcium transients in APP transgenic mice [132]. 21% of
cortical neurons demonstrate hyperactivity, with increased frequency
of spontaneous calcium transients, but only within 60 M proxim-
ity to an A plaque. A similar distance was reported for elevated
basal dendritic spine calcium levels [100]. The source of calcium
hyperactivity is dependent upon neuronal action potentials, as TTX
prevents all spontaneous calcium transients. Intriguingly, calcium
transient amplitudes do not differ between APP and wild-type
mice, suggesting only the frequency of transients is affected.
Spontaneous transients are presumed to be a consequence of
reduced inhibition as GABA, the main inhibitory neurotransmitter,
as activators decreased the frequency of spontaneous transients,
whereas GABA inhibitors in wild-type mice increased spontaneous
calcium transients. The consequences of these spontaneous cal-
cium transients could be the increase in dendritic spine calcium
reported in APP mice which lead to altered synaptic morphologies,
but also, due to the ordered nature of the transients, could also
trigger epileptic like seizures. Such seizures have been reported in
other APP mouse models [133] in which the removal of  was pro-
tective against aberrant neuronal activity, as well as in AD patients
themselves [134, 135].
A and mitochondrial calcium dyshomeostasis
Mitochondrial dyshomeostasis has been observed in AD brains,
as well as in transgenic mouse models of AD, and cell culture
models [136]. Mitochondria hold the key to cellular life or death,
firstly through the production of ATP, but also through the release
of pro-apoptotic signals such as cytochrome C. Mitochondria
buffer calcium and are involved in neuronal calcium homeostasis.
A, and A oligomers, associate with mitochondrial membranes
and have recently been shown to interact with cyclophilin D – part
of the mitochondrial permeability pore [69]. Notably, this interac-
tion makes mitochondria more susceptible to swelling in response
to calcium, and increases the likelihood of pore permeability tran-
sition. Pore permeability transition is associated with a collapse of
mitochondrial membrane potential and release of pro-apoptotic
proteins into the cell’s cytoplasm, leading to neuronal loss.
Furthermore, genetic ablation of cyclophilin D protected trans-
genic mice against A-induced cognitive deficits, implicating A
and mitochondria interactions in neuronal dysfunction and high-
lighting the importance of normal mitochondrial function to
proper synaptic transmission.
Current therapeutics
Given the apparent influence of calcium disturbances in the initia-
tion, progression or effects of the disease, can calcium modulators
be used as effective therapies for the disease? Currently two classes
of drug are used for the treatment of AD – the first are acetyl-
cholinesterase inhibitors, and the second consists of a single drug,
memantine, which is a partial NMDA receptor antagonist. Hence,
targeting NMDA receptor mediated calcium influx in AD patients 
is beneficial for cognition [137], as well as in mouse models of 
AD [138], cell culture models of A toxicity via attenuation of 
© 2009 The Author
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
J. Cell. Mol. Med. Vol 13, No 9A, 2009
2795
phosphorylation [139], and is also associated with a reduction in A
plaque pathology [140].
Other calcium influx pathway blockers have also been evalu-
ated in AD patients, although without sustained efficacy, including
the L-type voltage gated calcium channel blocker nimodipine
[141], and other calcium channel blockers associated with the car-
diovascular system [142]. Dimebon, an antihistamine, has been
shown to improve cognition in mild to moderate AD patients
[143], and has reported activity as an NMDA receptor antagonist,
as well being able to block voltage gated calcium channel currents,
although at concentrations that may be too high to be responsible
for the improvements in cognition [144]. Thus, targeting the
NMDA receptor appears to be beneficial for the disease, and future
drugs may refine this activity further. In the meantime, although
calcium channel blockers have not proven effect in patients with
the disease, targeting calcium influx may be able to delay or pre-
vent the onset of AD if given at the right time, or targeting specific
channels may be able to prevent the synaptotoxicity of A.
Conclusions
Calcium may play a vital role in any number of aspects of AD –
from modulating APP processing towards the amyloidogenic pro-
cessing pathway, to underlying memory and neuronal loss. In
vivo evidence has shown that A increases dendritic spine cal-
cium levels, impairs LTP and induces learning and memory
deficits, highlighting the synapse as a prime A target, although
age related changes in calcium homeostasis may allow the
buildup of pathologies associated with AD, through both direct
and indirect mechanisms. Synaptic transmission is highly
dependent upon tightly regulated calcium at both the pre- and
post-synaptic membranes and it is at these membranes all the ion
channels A has been reported to disrupt are clustered, likely
leading to synaptic dysfunction and more, while targeting NMDA
receptors with memantine is beneficial in AD patients, as well as
numerous models of the disease, placing calcium dyshomeosta-
sis firmly at the centre of the disease.
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